CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-09). The draft was written by AI, all 4 cited sources were opened and checked for existence, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 140 · Search date 2026-07-09 · Methodology v0.6

Artichoke leaf extract,
does it really help with Cholesterol, digestion, and liver?

30-Second Summary
C
Evidence Grade C · 55 · Safety caution
Blood and liver-enzyme values should be distinguished from clinical prevention effects.
What the
research shows
Artichoke leaf extract has human-study signals for LDL and total cholesterol, functional dyspepsia symptoms, and liver enzymes in fatty liver. However, cholesterol and liver enzymes are surrogate markers, and digestion studies are also limited, so broad claims such as cardiovascular-event prevention or liver detox are C.
What the
ads claim
Products in Korea and abroad combine 'cholesterol,' 'bile secretion,' 'digestion,' 'liver cleansing/detox,' and 'fatty liver.' Liver cleansing and detox are not clinically defined endpoints, so they should be distinguished from liver-enzyme studies.
*

Useful facts when choosing a product

  • Research doses vary widely, from 250 to 2700 mg/day of extract.
  • Caution is needed in people with Asteraceae-family plant allergy, gallstones, or bile-duct obstruction.
  • Improvements in LDL and ALT/AST are surrogate markers and are not the same as improved cardiovascular events or liver-disease prognosis.
  • Standardized constituents such as cynarin and chlorogenic acid can differ by product.
Gap Measurement · Verdict 140 · C 55
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Cochrane review of artichoke leaf extract for hypercholesterolemia considered the evidence uncertain because the number of studies was small and quality was limited. Lipid meta-analyses by Sahebkar and others reported signals for reductions in total cholesterol and LDL, but these are blood surrogate markers. The Holtmann 2003 RCT in 247 patients with functional dyspepsia reported improvements in symptoms and quality of life. Fatty-liver studies show signals for improvements in ALT/AST, ultrasound, and lipid measures, but they did not evaluate liver-related clinical events.

02

Why this is classified as C (55)

Cholesterol and liver enzymes are surrogate markers, so the maximum grade is C. The dyspepsia-symptom RCT uses a direct symptom endpoint, but the overall composite claim does not have enough large independent evidence to raise it to B. It is judged near the upper end of C, at 55 points.

Counterpoint. If a narrow symptom claim such as functional dyspepsia were evaluated separately, the score could be slightly higher. This file judges the composite claim for cholesterol, digestion, and liver.

Rejudgment record. Draft — Surrogate-marker centered, limited digestion-symptom RCT evidence, and composite claim.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Cochrane 2013Cochrane review3Independent reviewBlood cholesterolAssessed that evidence for lipid improvement with artichoke leaf extract was limited by study number and quality.Core
Sahebkar A et al. 2018Systematic review and meta-analysisMixedTotal cholesterol, LDL, and TGReported signals for improved blood lipids, but these are surrogate markers.Core
Holtmann G et al. 2003Randomized placebo-controlled trial247Possible industry tiesFunctional dyspepsia symptomsReported improvements in symptom scores and quality of life.Supporting
Study 4Randomized placebo-controlled trialMixedALT/AST, ultrasound, and lipidsReported signals for improved liver enzymes and lipid measures, but not clinical prognosis endpoints.Surrogate marker
§

Receipt — 4 References

Every cited source was opened and checked against the live page on 2026-07-09.

Cochrane. Artichoke leaf extract for treating hypercholesterolaemia. 2013.
checked
Sahebkar A, et al. The effects of artichoke on lipid profile: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018.
checked
Holtmann G, et al. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther. 2003.
checked
Panahi Y, et al. Artichoke leaf extract and non-alcoholic fatty liver disease randomized trials.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-09 · Corrections: none

Cite this verdict

Artichoke leaf extract x cholesterol, digestion, and liver Evidence Grade C card
[Chamgap] Artichoke leaf extract x cholesterol, digestion, and liver — Evidence Grade C·55. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/heart/artichoke-cholesterol-digestion-liver/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.